Ceramide mediates inhibition of the Akt/eNOS pathway by high levels of glucose in human vascular endothelial cells

J Pediatr Endocrinol Metab. 2013;26(1-2):31-8. doi: 10.1515/jpem-2012-0144.

Abstract

Objective: To investigate how ceramide mediates the effects of high-glucose-induced inhibition of the Akt/endothelial nitric oxide synthase (eNOS) signalling pathway in human vascular endothelial cells (HUVECs).

Materials and methods: NO levels were determined by ELISA. Endogenous ceramide levels were determined using a liquid chromatography-mass spectrometry assay. Akt and eNOS protein expressions were determined by Western blotting.

Results: High-glucose levels induce ceramide accumulation in a dose- and time-dependent manner (p<0.05). We also show that exposure of HUVECs to high-glucose conditions inhibits the insulin-mediated activation of Akt/eNOS signalling and the subsequent NO generation in a dose-dependent manner (p<0.05). Preventing de novo ceramide synthesis attenuated the antagonistic effects of high-glucose levels on the Akt/eNOS signalling pathway (p<0.05); conversely, inducing ceramide build-up augmented the inhibitory effects of high-glucose levels on the Akt/eNOS signalling pathway (p<0.05).

Conclusion: Ceramide is both necessary and sufficient for mediating the inhibition of the Akt/eNOS signalling pathway by high-glucose levels in endothelial cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Ceramides / metabolism
  • Ceramides / pharmacology*
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Endothelial Cells / drug effects*
  • Endothelial Cells / enzymology
  • Endothelial Cells / metabolism
  • Enzyme Activation / drug effects
  • Glucose / pharmacology*
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Insulin / pharmacology
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / metabolism*
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Oncogene Protein v-akt / metabolism*
  • Signal Transduction / drug effects
  • Time Factors

Substances

  • Ceramides
  • Insulin
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Oncogene Protein v-akt
  • Glucose